AURA
Aura Biosciences, Inc.
Key Financials
Operating Income
$-112791000
↓ 17.3%
Total Assets
$169.4M
↓ 7.2%
EPS (Diluted)
$-1.76
↓ 0.6%
Net Income
$-106191000
↓ 22.2%
Shareholders' Equity
$136.9M
↓ 9.9%
Total Liabilities
$32.5M
↑ 6.5%
Cash & Equivalents
$59.5M
↑ 87.8%
Operating Cash Flow
$-84742000.00
↓ 6.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/19/2026 | View on SEC |
| S-8 | 5/19/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| SCHEDULE 13D/A | 5/11/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 3 | 5/7/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| 424B5 | 5/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AURA |
| Company Name | Aura Biosciences, Inc. |
| CIK | 1501796 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617)500-8864 |